Expert Market Research highlights how the age-related macular degeneration market growth is being propelled by advancements in biologics, increasing healthcare accessibility, and strong demand for innovative eye care solutions. With global market size projected to surge from USD 10.46 Billion in 2024 to USD 26.40 Billion by 2034, industry trends point toward a future shaped by breakthrough therapies, personalized medicine, and expanded patient reach across developed and emerging economies.

Age-Related Macular Degeneration Market Overview

The age-related macular degeneration (AMD) market represents a rapidly expanding segment of the global ophthalmology industry, fueled by the rising prevalence of AMD among the elderly population. As a leading cause of vision loss in individuals aged 60 and above, AMD significantly impacts quality of life and healthcare costs. Technological advancements in diagnostics, targeted drug therapies, and innovative delivery mechanisms have transformed treatment approaches in recent years. Government and non-profit organizations are increasingly funding research to address unmet clinical needs, thereby supporting market growth. With growing awareness and an aging demographic, the AMD market is poised for strong performance throughout the forecast period.

Age-Related Macular Degeneration Market Size

In 2024, the global age-related macular degeneration market achieved a valuation of USD 10.46 Billion, driven primarily by an expanding geriatric population and a rise in AMD diagnosis rates worldwide. The demand for effective treatment options, especially anti-VEGF therapies, has surged due to their proven efficacy in slowing disease progression. Increased healthcare spending and accessibility to advanced ophthalmic care have further contributed to market expansion. Considering the increasing prevalence of both wet and dry AMD types, the market size is expected to witness robust growth in the coming years. By 2034, the market is projected to reach USD 26.40 Billion, reflecting a CAGR of 9.70% during the forecast period from 2025 to 2034.

Age-Related Macular Degeneration Market Trends

The AMD market is witnessing several notable trends shaping its future trajectory. The integration of artificial intelligence in retinal imaging is improving early detection rates and enabling precision diagnosis. Moreover, the increasing adoption of home monitoring tools and teleophthalmology services is enhancing patient engagement and reducing disease progression risks. Pharmaceutical companies are investing heavily in R&D for next-generation biologics and gene therapy approaches to provide longer-lasting treatment benefits with fewer injections. Additionally, combination therapies targeting multiple disease pathways are gaining traction to address cases resistant to standard anti-VEGF treatment. Sustainability trends, such as eco-friendly packaging of drugs and devices, are also influencing the market landscape.

Read full report: https://www.expertmarketresearch.com/reports/age-related-macular-degeneration-market/requestsample

Age-Related Macular Degeneration Market Opportunities and Challenges

Opportunities in the AMD market stem from the unmet medical need for effective dry AMD treatments, offering lucrative prospects for biotech firms. Expanding healthcare infrastructure in emerging economies is also opening new revenue streams, with governments increasingly prioritizing ophthalmic disease management. Rising health awareness campaigns and accessible screening programs further contribute to market penetration.

Challenges, however, remain significant. The high cost of advanced biologics often limits patient access, particularly in low-income regions. Regulatory hurdles and the time-consuming drug approval process can delay market entry for novel therapies. Additionally, treatment adherence issues, especially for patients requiring frequent intravitreal injections, may affect long-term outcomes. Overcoming these barriers will be crucial for sustained market success.

Age-Related Macular Degeneration Market Segmentation

• By Product:
  • Wet AMD
  • Dry AMD
• By Drug:
  • Lucentis
  • Eylea
  • Avastin
  • Others
• By Route of Administration:
  • Intravenous
  • Intravitreal
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Age-Related Macular Degeneration Market Growth

The AMD market’s growth is strongly linked to demographic trends, particularly the rapid increase in the global elderly population. Urban lifestyles, dietary patterns, and increased screen time are contributing to earlier onset and higher prevalence of AMD. Pharmaceutical innovations, particularly in anti-VEGF and sustained-release drug delivery systems, are improving patient outcomes and driving adoption. Favorable reimbursement policies in developed economies are encouraging more patients to seek advanced treatment options. Furthermore, cross-industry collaborations between biotech companies and ophthalmic device manufacturers are accelerating the commercialization of breakthrough therapies. With these factors combined, the market is set to experience steady double-digit growth in several regional segments over the next decade.

Age-Related Macular Degeneration Market Forecast

From 2025 to 2034, the AMD market is forecast to grow at a CAGR of 9.70%, supported by a mix of demographic, technological, and therapeutic advancements. Wet AMD treatments will continue to dominate revenue generation due to their higher treatment costs and frequency of administration. However, the anticipated launch of effective dry AMD therapies could significantly expand the market base. By 2034, the global market is projected to reach USD 26.40 Billion, nearly doubling from its 2024 value. Growth will be most pronounced in Asia Pacific and Latin America due to expanding healthcare coverage and awareness programs, while North America and Europe will remain strongholds for innovation and product launches.

Age-Related Macular Degeneration Market Competitor Analysis

• Bayer AG – Leading player in anti-VEGF therapy for wet AMD with strong global distribution.
• F. Hoffmann-La Roche Ltd. – Innovator in ophthalmology with an extensive AMD treatment pipeline.
• Novartis AG – Global healthcare leader with a diverse AMD product portfolio.
• Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) – Pioneering high-efficacy AMD drugs with long-lasting treatment effects.
• Others – Emerging biotech firms and regional players enhancing market competition.

Find More Report:

CDMO Market: https://bit.ly/45yUr3r

Biologics Market: https://bit.ly/3GOIayw

Medical Wellness Market: https://bit.ly/4mac6UT